Comparative Pharmacology
Head-to-head clinical analysis: MARCAINE HYDROCHLORIDE versus ZYNRELEF KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MARCAINE HYDROCHLORIDE versus ZYNRELEF KIT.
MARCAINE HYDROCHLORIDE vs ZYNRELEF KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, reversibly inhibiting nerve impulse propagation, particularly in sensory fibers.
Zynrelef is a fixed-dose combination of bupivacaine and meloxicam. Bupivacaine blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction. Meloxicam inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and inflammation.
Adults: 0.5% solution infiltrated up to 175 mg (35 mL) for minor procedures; for major procedures, up to 225 mg (45 mL) with epinephrine. Repeat doses at 3-hour intervals. Maximum dose 400 mg with epinephrine.
Instillation into the surgical site: 20 mL (300 mg bupivacaine and 9.3 mg meloxicam) as a single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 to 3.5 hours in adults; may be prolonged in neonates (8-12 hours) or patients with hepatic impairment.
Terminal half-life of bupivacaine (component) is 3.5 hours; for meloxicam (component) is 20 hours. Clinical context: bupivacaine half-life prolonged in hepatic impairment; meloxicam half-life prolonged in elderly (up to 25 hours)
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Metabolites are excreted renally, with a small amount in feces via biliary elimination.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Local Anesthetic
Local Anesthetic and NSAID Combination